{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:59:44Z","timestamp":1788026384028,"version":"build-2784847793"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gorlin syndrome is a genetic condition associated with the occurrence of SHH activated medulloblastoma, basal cell carcinoma, macrocephaly and other congenital anomalies. It is caused by heterozygous pathogenic variants in <jats:italic>PTCH1<\/jats:italic> or <jats:italic>SUFU<\/jats:italic>. In this study we included 16 patients from the HIT2000, HIT2000interim, I-HIT-MED, observation registry and older registries such as HIT-SKK87, HIT-SKK92 (1987 \u2013 2020) with genetically confirmed Gorlin syndrome, harboring 10 <jats:italic>PTCH1<\/jats:italic> and 6 <jats:italic>SUFU<\/jats:italic> mutations. Nine patients presented with desmoplastic medulloblastomas (DMB), 6 with medulloblastomas with extensive nodularity (MBEN) and one patient with classic medulloblastoma (CMB); all tumors affected the cerebellum, vermis or the fourth ventricle. SHH activation was present in all investigated tumors (14\/16); DNA methylation analysis (when available) classified 3 tumors as iSHH-I and 4 tumors as iSHH-II. Age at diagnosis ranged from 0.65 to 3.41 years. All but one patient received chemotherapy according to the HIT-SKK protocol. Ten patients were in complete remission after completion of primary therapy; four subsequently presented with PD. No patient received radiotherapy during initial treatment. Five patients acquired additional neoplasms, namely basal cell carcinomas, odontogenic tumors, ovarian fibromas and meningioma. Developmental delay was documented in 5\/16 patients. Overall survival (OS) and progression-free survival (PFS) between patients with <jats:italic>PTCH1<\/jats:italic> or <jats:italic>SUFU<\/jats:italic> mutations did not differ statistically (10y-OS 90% <jats:italic>vs<\/jats:italic>. 100%, p=0.414; 5y-PFS 88.9% \u00b1 10.5% <jats:italic>vs<\/jats:italic>. 41.7% \u00b1 22.2%, p=0.139). Comparing the Gorlin patients to all young, SHH activated MBs in the registries (10y-OS 93.3% \u00b1 6.4% <jats:italic>vs<\/jats:italic>. 92.5% \u00b1 3.3%, p=0.738; 10y-PFS 64.9%+-16.7% <jats:italic>vs<\/jats:italic>. 83.8%+-4.5%, p=0.228) as well as comparing Gorlin M0 SKK-treated patients to all young, SHH activated, M0, SKK-treated MBs in the HIT-MED database did not reveal significantly different clinical outcomes (10y-OS 88.9% \u00b1 10.5% <jats:italic>vs<\/jats:italic>. 88% \u00b1 4%, p=0.812; 5y-PFS 87.5% \u00b1 11.7% <jats:italic>vs<\/jats:italic>. 77.7% \u00b1 5.1%, p=0.746). Gorlin syndrome should be considered in young children with SHH activated medulloblastoma, especially DMB and MBEN but cannot be ruled out for CMB. Survival did not differ to patients with SHH-activated medulloblastoma with unknown germline status or between <jats:italic>PTCH1<\/jats:italic> and <jats:italic>SUFU<\/jats:italic> mutated patients. Additional neoplasms, especially basal cell carcinomas, need to be expected and screened for. Genetic counselling should be provided for families with young medulloblastoma patients with SHH activation.<\/jats:p>","DOI":"10.3389\/fonc.2021.756025","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:17:45Z","timestamp":1638274665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort"],"prefix":"10.3389","volume":"11","author":[{"given":"Katja","family":"Kloth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Obrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Warmuth-Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mynarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary Cancer Predisposition Syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.med.52.1.371","article-title":"Genetic Testing for Cancer Predisposition","volume":"52","author":"Eng","year":"2001","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.02.017","article-title":"Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes","volume":"94","author":"Samadder","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24555","article-title":"Update on Pediatric Cancer Predisposition Syndromes","volume":"60","author":"Schiffman","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38142","article-title":"Childhood Cancer Predisposition Syndromes-A Concise Review and Recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology","volume":"173","author":"Ripperger","year":"2017","journal-title":"Am J Med Genet A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11912-019-0836-9","article-title":"Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial Impacts","volume":"21","author":"Mitchell","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5699","article-title":"Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors","volume":"2","author":"Parsons","year":"2016","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline Mutations in Predisposition Genes in Pediatric Cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0595","article-title":"Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome","volume":"23","author":"Foulkes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ncl.2007.07.008","article-title":"Genetic Causes of Brain Tumors: Neurofibromatosis, Tuberous Sclerosis, Von Hippel-Lindau, and Other Syndromes","volume":"25","author":"Farrell","year":"2007","journal-title":"Neurol Clin"},{"key":"B11","volume-title":"Medulloblastoma","author":"Mahapatra","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01424-X","article-title":"Medulloblastoma: Signalling a Change in Treatment","volume":"5","author":"Gilbertson","year":"2004","journal-title":"Lancet Oncol"},{"key":"B13","volume-title":"Annual Report 2019","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and Prevalence of Genetic Predisposition in Medulloblastoma: A Retrospective Genetic Study and Prospective Validation in a Clinical Trial Cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature22973","article-title":"The Whole-Genome Landscape of Medulloblastoma Subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.19.00577","article-title":"Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma","volume":"38","author":"Begemann","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-020-2164-5","article-title":"Germline Elongator Mutations in Sonic Hedgehog Medulloblastoma","volume":"580","author":"Waszak","year":"2020","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566822","article-title":"Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era","volume":"10","author":"Carta","year":"2020","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09854-1","article-title":"Molecular Stratifications, Biomarker Candidates and New Therapeutic Options in Current Medulloblastoma Treatment Approaches","volume":"39","author":"Menyhart","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.04.009","article-title":"The Incidence of Medulloblastomas and Primitive Neurectodermal Tumours in Adults and Children","volume":"19","author":"Smoll","year":"2012","journal-title":"J Clin Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000071316","article-title":"Medulloblastoma: Present Concepts of Stratification Into Risk Groups","volume":"39","author":"Packer","year":"2003","journal-title":"Pediatr Neurosurg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging Issues in Pediatric Oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26042","article-title":"Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated With Sequential High-Dose Chemotherapy","volume":"63","author":"Lafay-Cousin","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042176","article-title":"Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone","volume":"352","author":"Rutkowski","year":"2005","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-084","article-title":"Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy and Deferred Radiotherapy","volume":"11","author":"Rutkowski","year":"2009","journal-title":"Neuro Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03057","article-title":"Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort","volume":"38","author":"Mynarek","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa102","article-title":"Excellent Outcome of Young Children With Nodular Desmoplastic Medulloblastoma Treated on \"Head Start\" III: A Multi-Institutional, Prospective Clinical Trial","volume":"22","author":"Dhall","year":"2020","journal-title":"Neuro Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2023","article-title":"Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome\u2013a New Clinical Perspective","volume":"15","author":"Garre","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.04.007","article-title":"A Recurrent Mosaic Mutation in SMO, Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones Syndrome","volume":"98","author":"Twigg","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B32","first-page":"12","article-title":"The Nevoid Basal Cell Carcinoma Syndrome","volume":"19","author":"Anderson","year":"1967","journal-title":"Am J Hum Genet"},{"key":"B33","volume-title":"Nevoid Basal Cell Carcinoma Syndrome. GeneReviews\u00ae","author":"Evans","year":"2002"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12458","article-title":"Molecular Evidence of Type 2 Mosaicism in Gorlin Syndrome","volume":"169","author":"Torrelo","year":"2013","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00845","article-title":"Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children\u2019s Oncology Group (Acns1221)","volume":"38","author":"Lafay-Cousin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz036.079","article-title":"GENE-08. The MNP 2.0 Study: Prospective Integration Of DNA Methylation Profiling In CNS Tumor Diagnostics","volume":"21","author":"Sturm","year":"2019","journal-title":"Neuro-Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480","article-title":"The Landscape of Genomic Alterations Across Childhood Cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"B39","volume-title":"Gorlin Syndrome (Basal Cell Nevus)","author":"Spiker","year":"2020"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196005052621803","article-title":"Multiple Nevoid Basal-Cell Epithelioma, Jaw Cysts and Bifid Rib. A Syndrome","volume":"262","author":"Gorlin","year":"1960","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-619","article-title":"Rhabdomyosarcomas and Radiation Hypersensitivity in a Mouse Model of Gorlin Syndrome","volume":"4","author":"Hahn","year":"1998","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-013-9623-1","article-title":"Frameshift Mutation in the PTCH2 Gene can Cause Nevoid Basal Cell Carcinoma Syndrome","volume":"12","author":"Fujii","year":"2013","journal-title":"Fam Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41439-019-0041-2","article-title":"A Healthy Individual With a Homozygous PTCH2 Frameshift Variant: Are Variants of PTCH2 Associated With Nevoid Basal Cell Carcinoma Syndrome","volume":"6","author":"Altaraihi","year":"2019","journal-title":"Hum Genome Var"},{"key":"B44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccr.2014.02.004","article-title":"Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition","volume":"25","author":"Kool","year":"2014","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox228","article-title":"Germline SUFU Mutation Carriers and Medulloblastoma: Clinical Characteristics, Cancer Risk, and Prognosis","volume":"20","author":"Guerrini-Rousseau","year":"2017","journal-title":"Neuro-Oncology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00247-z","article-title":"Current Recommendations for Cancer Surveillance in Gorlin Syndrome: A Report From the SIOPE Host Genome Working Group (SIOPE HGWG)","volume":"20","author":"Guerrini-Rousseau","year":"2021","journal-title":"Fam Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline Mutations in SUFU Cause Gorlin Syndrome-Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0800-8","article-title":"Medulloblastoma: Clinicopathological Correlates of SHH, WNT, and non-SHH\/WNT Molecular Subgroups","volume":"121","author":"Ellison","year":"2011","journal-title":"Acta Neuropathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature26000","article-title":"DNA Methylation-Based Classification of Central Nervous System Tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.5414\/NP300999","article-title":"Update on the Integrated Histopathological and Genetic Classification of Medulloblastoma - a Practical Diagnostic Guideline","volume":"35","author":"Pietsch","year":"2016","journal-title":"Clin Neuropathol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral Heterogeneity Within Medulloblastoma Subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30204-3","article-title":"Risk-Adapted Therapy for Young Children With Medulloblastoma (SJYC07): Therapeutic and Molecular Outcomes From a Multicentre, Phase 2 Trial","volume":"19","author":"Robinson","year":"2018","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor025","article-title":"Treatment of Young Children With Localized Medulloblastoma by Chemotherapy Alone: Results of the Prospective, Multicenter Trial HIT 2000 Confirming the Prognostic Impact of Histology","volume":"13","author":"von Bueren","year":"2011","journal-title":"Neuro Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy059.423","article-title":"MBCL-27. Response Of Recurrent Malignant Childhood CNS Tumors To A Memmat Based Metronomic Antiangiogenic Combination Therapy Varies Dependent On Tumor Type: Experience In 71 Patients","volume":"20","author":"Slavc","year":"2018","journal-title":"Neuro-Oncology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy059.435","article-title":"MBCL-39. Medulloblastoma In Patients With Gorlin Syndrome: Results From The Hit Study Group","volume":"20","author":"Meissner","year":"2018","journal-title":"Neuro-Oncology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.08.004","article-title":"Genetics of Common Pediatric Brain Tumors","volume":"104","author":"Malbari","year":"2020","journal-title":"Pediatr Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1276-0","article-title":"Prognostic Significance of Clinical, Histopathological, and Molecular Characteristics of Medulloblastomas in the Prospective HIT2000 Multicenter Clinical Trial Cohort","volume":"128","author":"Pietsch","year":"2014","journal-title":"Acta Neuropathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.41.11.1005","article-title":"A Second Brain Tumour and Irradiation","volume":"41","author":"Robinson","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3171\/jns.1994.81.5.0690","article-title":"Outcome for Children With Medulloblastoma Treated With Radiation and Cisplatin, CCNU, and Vincristine Chemotherapy","volume":"81","author":"Packer","year":"1994","journal-title":"J Neurosurg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/neuonc\/nos267","article-title":"Survival and Secondary Tumors in Children With Medulloblastoma Receiving Radiotherapy and Adjuvant Chemotherapy: Results of Children's Oncology Group Trial A9961","volume":"15","author":"Packer","year":"2012","journal-title":"Neuro-Oncology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2006.047753","article-title":"Mosaicism in Neurofibromatosis Type 2: An Update of Risk Based on Uni\/Bilaterality of Vestibular Schwannoma at Presentation and Sensitive Mutation Analysis Including Multiple Ligation-Dependent Probe Amplification","volume":"44","author":"Evans","year":"2007","journal-title":"J Med Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ng916","article-title":"Mutations in SUFU Predispose to Medulloblastoma","volume":"31","author":"Taylor","year":"2002","journal-title":"Nat Genet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2503","article-title":"Basal Cell Carcinomas: Attack of the Hedgehog","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"adv00434","DOI":"10.2340\/00015555-3797","article-title":"A Novel Case of Gorlin Syndrome Mosaicism Involving an SMO Gene Mutation: Clinical, Histological and Molecular Analysis of Basaloid Tumours","volume":"101","author":"Ighilahriz","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.34216","article-title":"Microdeletion 9q22.3 Syndrome Includes Metopic Craniosynostosis, Hydrocephalus, Macrosomia, and Developmental Delay","author":"Muller","year":"2012","journal-title":"Am J Med Genet A"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.756025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:17:51Z","timestamp":1638274671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.756025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":65,"alternative-id":["10.3389\/fonc.2021.756025"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.756025","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"article-number":"756025"}}